Latest Regulatory Approvals News

Australia’s ANSTO has independently confirmed that Lindian Resources’ Kangankunde monazite concentrate is exempt from radioactive transport classification, simplifying export logistics and lowering downstream costs.

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

Caravel Minerals confirms its Definitive Feasibility Study for the Caravel Copper Project remains on track for mid-2026, while regulatory water investigations push the Final Investment Decision to late 2027. Meanwhile, strategic talks with Adani advance steadily.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.

Sea Forest Limited has reported a remarkable 236% increase in SeaFeed revenue for the first half of 2026, surpassing breakeven cattle commitments and securing new international partnerships.

Forrestania Resources has agreed to acquire multiple gold exploration tenements from Flynn Gold, consolidating its position in the highly prospective Forrestania Hub of Western Australia. The deal supports Forrestania’s growth strategy and near-term production goals.

AuMEGA Metals has confirmed a $30 million oversubscribed financing led by Condire Investors to fund expanded drilling and exploration in Newfoundland. The capital raise is structured in two tranches, with the first closing expected in early March and the second pending shareholder approval.

Pacgold has secured a profit share agreement to tap into the high-grade, historically mined Wadnaminga Project near its White Dam operations, aiming to fast-track gold production from legacy tailings and untested lodes.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.